Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: BIGFRED who wrote (1132)	6/23/1998 9:25:00 AM
From: Brad	Read Replies (1) \| Respond to of 4650

Hi Fred! In response to your questions... >>1- Kit sales will start in September 1998 and a larger test of 300 patients will also start in September 1998.?<< The Kit sales starting in September 1998 are those to cytopathology labs. Those kits do NOT require FDA approval because the test is "non-invasive." The larger 300 patient study starting in September will provide further evidence to those people in the medical community that need more convincing. It also provides more documentation for the "treatment" part of the technology that WILL require FDA approval. >>2- Since the results will be presented in September of 1998 to FDA, how can we also start selling the kits so soon?<< The "early detection" sputum test is "non-invasive" and does NOT require FDA approval. Only the "treatment" part of the technology will require FDA approval. Two separate things. >>3- Biomoda is expected to be very active in the 4th quarter of 1998, per CEO of Biomoda....Could you elaborate?<< They intend to be in doing Full Marketing of the "early detection" sputum test. They intend to market to cytopathology labs first, then to hospitals, and they will be working on mass market retail as well. The "early detection" test is very simple and can be sold to consumers who do the test at home and then deliver it (or mail in) to a diagnostic center (which initially will be cytopathology labs, as I understand it.) If they have a deal with one of the major pharmaceutical firms by September, the marketing efforts of that firm could also be underway, depending on the role of that firm. >>4- So, it is not a 100.00 dollar per test like we were told. Only 10.00 dollars. This is fantastic.<< I agree! That makes the test easy and cheap to use. Smokers might be testing themselves on a very frequent basis. I will provide an "OVERVIEW" update later today that will include the names, phone numbers and e-mail addresses for contacting Biomoda, so anyone can verify my understanding of the situation. It never hurts to have "a second opinion." :-) Best wishes, Brad